article thumbnail

Trends in prognosis and use of SGLT2i and GLP-1 RA in patients with diabetes and coronary artery disease

Cardiovascular Diabetology

Objective To explore trends in prognosis and use of glucose-lowering drugs (GLD) in patients with diabetes and coronary artery disease (CAD). Information on GLD (dispended 6 months before or after coronary angiography) was collected from the Swedish Prescribed Drug Registry.

article thumbnail

ANDROMEDA Meta-Analysis: PCB Angioplasty vs. DES Implantation

American College of Cardiology

In patients undergoing PCI for de novo small-vessel coronary artery disease (SV-CAD), paclitaxel-coated balloon (PCB) angioplasty was associated with a reduction in the primary endpoint of major adverse cardiac events (MACE).

article thumbnail

Drug-Coated Balloons for the Treatment of CAD

JAMA Cardiology

This narrative review discusses drug-coated balloon angioplasty as an alternative to drug-eluting stent for percutaneous coronary intervention in patients with in-stent restenosis and de novo coronary artery disease.

article thumbnail

Submaximal Angioplasty for Severe Intracranial Atherosclerotic Stenosis: Benefit of Revascularization at Last

Stroke Journal

The longstanding benefits of percutaneous angioplasty and stenting in coronary artery disease, where atherosclerosis is the overarching cause in nearly all cases, provided a compelling rationale for exploring similar interventions in intracranial atherosclerotic stenosis.

article thumbnail

Impact of Diabetes on Outcomes in Left Main Coronary Revascularization: PCI vs. CABG

Cardiology Update

Left main coronary artery disease (CAD) and diabetes pose significant challenges in cardiovascular care, often leading to adverse outcomes. However, the comparative long-term efficacy of percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG) in patients with these conditions remains unclear.

Diabetes 122
article thumbnail

Boston Scientific Receives FDA Approval for the AGENT Drug-Coated Balloon

DAIC

Food and Drug Administration ( FDA ) approval for the AGENT Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue. vs. 28.7%; P=0.006).

Stent 105
article thumbnail

Understanding the Difference Between Heart Attack and Cardiac Arrest

MIBHS

Without immediate intervention, sudden cardiac death can occur within minutes.